Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?

Lipsitch M, Siber GR.

MBio. 2016 Jun 7;7(3). pii: e00428-16. doi: 10.1128/mBio.00428-16. Review.

2.

Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile.

Picard MD, Bodmer JL, Gierahn TM, Lee A, Price J, Cohane K, Clemens V, DeVault VL, Gurok G, Kohberger R, Higgins DE, Siber GR, Flechtner JB, Geisler WM.

Clin Vaccine Immunol. 2015 Nov;22(11):1206-18. doi: 10.1128/CVI.00247-15. Epub 2015 Oct 7.

3.

Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors.

Long D, Skoberne M, Gierahn TM, Larson S, Price JA, Clemens V, Baccari AE, Cohane KP, Garvie D, Siber GR, Flechtner JB.

Virology. 2014 Sep;464-465:296-311. doi: 10.1016/j.virol.2014.07.018. Epub 2014 Aug 9.

4.

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, Gruber WC, Lockhart S, Burkhardt O, Welte T, Lode HM.

Clin Infect Dis. 2008 Apr 1;46(7):1015-23. doi: 10.1086/529142. Erratum in: Clin Infect Dis. 2008 May 1;46(9):1488. Schmöele-Thoma, B [corrected to Schmöle-Thoma, B].

PMID:
18444818
5.

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, Gruber W, Siber GR, Lockhart SP.

Vaccine. 2007 Aug 14;25(33):6164-6. Epub 2007 Jun 26.

PMID:
17629361
6.

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R.

Vaccine. 2007 May 10;25(19):3816-26. Epub 2007 Feb 21.

PMID:
17368878
7.

Contributions of Native Americans to the global control of infectious diseases.

Santosham M, Reid R, Chandran A, Millar EV, Watt JP, Weatherholtz R, Donaldson C, Croll J, Moulton LH, Thompson CM, Siber GR, O'Brien KL.

Vaccine. 2007 Mar 22;25(13):2366-74. Epub 2006 Sep 18. Review.

PMID:
17069936
8.

Evaluation of the indirect effects of a pneumococcal vaccine in a community-randomized study.

Moulton LH, O'Brien KL, Reid R, Weatherholtz R, Santosham M, Siber GR.

J Biopharm Stat. 2006;16(4):453-62.

PMID:
16892907
9.
10.
11.

Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation.

Shahid NS, Steinhoff MC, Roy E, Begum T, Thompson CM, Siber GR.

Vaccine. 2002 May 22;20(17-18):2404-9.

PMID:
12009297
12.

Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.

Santosham M, Englund JA, McInnes P, Croll J, Thompson CM, Croll L, Glezen WP, Siber GR.

Pediatr Infect Dis J. 2001 Oct;20(10):931-40.

PMID:
11642626
13.

Design of a group-randomized Streptococcus pneumoniae vaccine trial.

Moulton LH, O'Brien KL, Kohberger R, Chang I, Reid R, Weatherholtz R, Hackell JG, Siber GR, Santosham M.

Control Clin Trials. 2001 Aug;22(4):438-52.

PMID:
11514043
14.
15.

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Hausdorff WP, Bryant J, Paradiso PR, Siber GR.

Clin Infect Dis. 2000 Jan;30(1):100-21.

PMID:
10619740
17.

Simultaneous vitamin A administration at routine immunization contact enhances antibody response to diphtheria vaccine in infants younger than six months.

Rahman MM, Mahalanabis D, Hossain S, Wahed MA, Alvarez JO, Siber GR, Thompson C, Santosham M, Fuchs GJ.

J Nutr. 1999 Dec;129(12):2192-5.

PMID:
10573548
18.

Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.

Bruss JB, Siber GR.

Clin Diagn Lab Immunol. 1999 Jul;6(4):464-70.

19.

Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin.

Bruss JB, Malley R, Halperin S, Dobson S, Dhalla M, Mciver J, Siber GR.

Pediatr Infect Dis J. 1999 Jun;18(6):505-11.

PMID:
10391179
20.

Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients.

Molrine DC, Siber GR, Samra Y, Shevy DS, MacDonald K, Cieri R, Ambrosino DM.

J Infect Dis. 1999 Feb;179(2):513-7.

PMID:
9878041
21.
23.

PCPP as a parenteral adjuvant for diverse antigens.

Payne LG, Van Nest G, Barchfeld GL, Siber GR, Gupta RK, Jenkins SA.

Dev Biol Stand. 1998;92:79-87.

PMID:
9554261
24.

Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.

Gupta RK, Chang AC, Siber GR.

Dev Biol Stand. 1998;92:63-78. Review.

PMID:
9554260
25.

Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats.

Stack AM, Malley R, Thompson CM, Kobzik L, Siber GR, Saladino RA.

J Infect Dis. 1998 Apr;177(4):986-90.

PMID:
9534972
26.

Haemophilus influenzae type b-specific antibody in infants after maternal immunization.

Englund JA, Glezen WP, Thompson C, Anwaruddin R, Turner CS, Siber GR.

Pediatr Infect Dis J. 1997 Dec;16(12):1122-30.

PMID:
9427456
28.

Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats.

Saladino RA, Stack AM, Fleisher GR, Thompson CM, Briles DE, Kobzik L, Siber GR.

Infect Immun. 1997 Nov;65(11):4701-4.

30.

Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid.

Gupta RK, Chang AC, Griffin P, Rivera R, Guo YY, Siber GR.

Vaccine. 1997 Apr-May;15(6-7):672-8.

PMID:
9178469
31.

Methods for estimating serological correlates of protection.

Siber GR.

Dev Biol Stand. 1997;89:283-96. Review. No abstract available.

PMID:
9272362
32.

A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats .

Stack AM, Saladino RA, Siber GR, Thompson C, Marra MN, Novitsky TJ, Fleisher GR.

Crit Care Med. 1997 Jan;25(1):101-5. Erratum in: Crit Care Med 1997 Mar;25(3):558.

PMID:
8989184
33.

Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin.

Gupta CK, Leszczynski J, Gupta RK, Siber GR.

Vaccine. 1996 Oct;14(15):1417-20. Erratum in: Vaccine 1997 Feb;15(2):247.

PMID:
8994316
34.

In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid.

Gupta RK, Chang AC, Griffin P, Rivera R, Siber GR.

Vaccine. 1996 Oct;14(15):1412-6. Erratum in: Vaccine 1997 Feb;15(2):247.

PMID:
8994315
35.

Association of placental transfer of anti-Haemophilus influenzae type b polysaccharide antibodies with their V regions.

Park MK, Englund JA, Glezen WP, Siber GR, Nahm MH.

Vaccine. 1996 Sep;14(13):1219-22.

PMID:
8961508
36.

Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis.

Weiner DL, Kuppermann N, Saladino RA, Thompson CM, Novitsky TJ, Siber GR, Fleisher GR.

Crit Care Med. 1996 Sep;24(9):1514-7.

PMID:
8797624
37.

Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus.

Brubaker JO, Thompson CM, Morrison LA, Knipe DM, Siber GR, Finberg RW.

J Immunol. 1996 Aug 15;157(4):1598-604.

PMID:
8759744
38.

Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children.

Simoes EA, Groothuis JR, Tristram DA, Allessi K, Lehr MV, Siber GR, Welliver RC.

J Pediatr. 1996 Aug;129(2):214-9.

PMID:
8765618
39.

High-dose recombinant endotoxin neutralizing protein improves survival in rabbits, with Escherichia coli sepsis.

Saladino RA, Stack AM, Thompson C, Sattler F, Novitsky TJ, Siber GR, Fleisher GR.

Crit Care Med. 1996 Jul;24(7):1203-7.

PMID:
8674336
40.
41.

Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation.

De Vincenzo JP, Leombruno D, Soiffer RJ, Siber GR.

Bone Marrow Transplant. 1996 Jun;17(6):1051-6.

PMID:
8807113
42.

Pulsed controlled-released system for potential use in vaccine delivery.

Sanchez A, Gupta RK, Alonso MJ, Siber GR, Langer R.

J Pharm Sci. 1996 Jun;85(6):547-52.

PMID:
8773947
43.

Diphtheria antitoxin levels in US blood and plasma donors.

Gupta RK, Griffin P Jr, Xu J, Rivera R, Thompson C, Siber GR.

J Infect Dis. 1996 Jun;173(6):1493-7.

PMID:
8648228
46.

Formation and cell-medium partitioning of autoinhibitory free fatty acids and cyclodextrin's effect in the cultivation of Bordetella pertussis.

Frohlich BT, d'Alarcao M, Feldberg RS, Nicholson ML, Siber GR, Swartz RW.

J Biotechnol. 1996 Feb 28;45(2):137-48.

PMID:
9147447
47.

Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens.

Gupta RK, Varanelli CL, Griffin P, Wallach DF, Siber GR.

Vaccine. 1996 Feb;14(3):219-25. Erratum in: Vaccine 1996 Jun;14(8):1.

PMID:
8920703
48.

Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine.

Schwendeman SP, Costantino HR, Gupta RK, Tobio M, Chang AC, Alonso MJ, Siber GR, Langer R.

Dev Biol Stand. 1996;87:293-306.

PMID:
8854030
49.

Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.

Gupta RK, Anderson R, Cecchini D, Rost B, Griffin P Jr, Benscoter K, Xu J, Montanez-Ortiz L, Siber GR.

Dev Biol Stand. 1996;86:283-96.

PMID:
8785957

Supplemental Content

Loading ...
Support Center